The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not significantly extend survival without disease worsening in people with newly-diagnosed advanced ovarian cancer, a recent trial shows. While the IMagyn050 Phase 3 trial (NCT03038100) failed to meet one of its primary endpoints, researchers are gathering more data to determine whether…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
$2.2M Awarded to Collaboration Researching Rare Form of Ovarian Cancer
A research collaboration led by the Hudson Institute of Medical Research as been awarded a $2.2-million grant to advance knowledge about ovarian granulosa cell tumors (GCT) and ultimately improve the outcomes of patients with this rare form of ovarian cancer. The multi-faceted research project will focus on mapping genetic mutations in GCTs, as well as…
3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients
An ongoing observational registry study is evaluating Kiyatec‘s novel technology, in which a patient’s own tumor tissue is cultured in a lab dish and exposed to different therapies as a means to predict treatment response in women with ovarian cancer. The 3D-PREDICT trial (NCT03561207) is studying the company’s patient-specific Ex Vivo 3D Cell Culture (EV3D)…
Laser Focal Therapy Effective, Causes Few Side Effects, 10-Year Trial Data Shows
Image-guided laser focal therapy is as effective as radical prostate removal surgery at treating men with localized prostate cancer, without the added risks of infection, incontinence, and erectile dysfunction, according to 10-year interim data from a Phase 2 trial. The trial findings were slated to be presented in a poster, “Outpatient Trans-Rectal MR-Guided Laser Focal…
University of Colorado Launches PreView Medical for PC Diagnosis, Treatment
The University of Colorado Anschutz Medical Campus, led by CU Innovations, has partnered with medical technology entrepreneurs Jonathan Gasson and Sharon Lake to form a new company called PreView Medical, which will focus on the development and optimization of new diagnostic procedures and treatments for prostate cancer. PreView Medical’s ClariCore System is based on a…
Vaccine Shows Promise in Advanced Prostate Cancer, Proof-of-Concept Study Shows
YourVaccx, a new type of cancer vaccine developed by ImmunSYS, is safe and shows promising effectiveness in patients with metastatic prostate cancer and other difficult-to-treat advanced solid tumors, a proof-of-concept study shows. Study findings were presented in a poster titled, “Regression of metastatic cancer and abscopal effects following in situ vaccination by cryosurgical tumor cell…
Study: Tests Used to Predict Response to PARP Inhibitors Yield Inconsistent Result
Tests used in clinical trials of ovarian cancer to determine if tumors lack the ability to repair their DNA — a status termed “homologous recombination deficiency” (HRD), and likely would respond to treatment with PARP inhibitors — yield inconsistent results, a recent study shows. Study findings were presented in the poster “Comparison of genomic instability test…
Liposomal Doxorubicin-based Regimen Improves Outcomes in Platinum-sensitive Ovarian Cancer
Second-line treatment with a combination of bevacizumab plus the chemotherapies carboplatin and pegylated liposomal doxorubicin may significantly improve the outcomes of platinum-sensitive ovarian cancer patients, compared to standard treatment, findings from a Phase 3 trial suggest. Women who received this experimental combination in the ENGOT-ov18 trial (NCT01837251) lived significantly longer without disease progression and experienced…
Pamiparib Granted Priority Review in China for Treatment of Advanced Ovarian Cancer
China’s regulatory agency has granted priority review status to BeiGene‘s new drug application (NDA) requesting the approval of pamiparib, its investigational PARP inhibitor, for the treatment of advanced ovarian cancers. Priority review is granted in China to reduce the time to review and approve promising therapies that address urgent clinical needs. The NDA specifically covers patients with advanced ovarian, fallopian…
PARP Inhibitor Pamiparib Under Review in China to Treat Advanced Ovarian Cancer
China’s regulatory agency has agreed to consider a request that pamiparib, BeiGene‘s investigational PARP inhibitor, be approved to treat people with advanced ovarian cancers after at least two prior lines of chemotherapy. The company’s new drug application (NDA), submitted to the Center for Drug Evaluation of the Chinese National Medical Products Administration, is specifically for patients with…
Small Inhibitor May Boost Effectiveness of PARP Inhibitors in Some Ovarian Cancers, Mouse Study Finds
A small inhibitor that prevents cells from making ribosomes — the machinery used to produce proteins — may improve the effectiveness of PARP inhibitors in ovarian cancers with mutations in DNA repair genes, a study in mice found. This inhibitor is a promising approach for ovarian cancers that are no longer susceptible to platinum-based chemotherapy or PARP…
FDA Office Favors Antibody-drug Conjugate for Advanced Multiple Myeloma
An office of the U.S. Food and Drug Administration (FDA has recommended that belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, be approved for heavily pretreated relapsed or refractory multiple myeloma patients. The recommendation by the FDA’s Oncologic Drugs Advisory Committee is for patients who had at least four prior lines of treatment, including an immunomodulatory agent, a proteasome inhibitor,…